Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics
Scarce information concerning the inoculum effect (InE) of methicillin-susceptible Staphylococcus aureus (MSSA) against broad-spectrum β-lactam antibiotics is available. We investigated the InE of MSSA against ceftriaxone, cefepime, meropenem, ampicillin/sulbactam and piperacillin/tazobactam. The ba...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2019-01, Vol.38 (1), p.67-74 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 74 |
|---|---|
| container_issue | 1 |
| container_start_page | 67 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 38 |
| creator | Song, Kyoung-Ho Jung, Sook-In Lee, Shinwon Park, Sohee Kim, Eu Suk Park, Kyung-Hwa Park, Wan Beom Choe, Pyoeng Gyun Kim, Young Keun Kwak, Yee Gyung Kim, Yeon-Sook Jang, Hee-Chang Kiem, Sungmin Kim, Hye-In Kim, Hong Bin |
| description | Scarce information concerning the inoculum effect (InE) of methicillin-susceptible
Staphylococcus aureus
(MSSA) against broad-spectrum β-lactam antibiotics is available. We investigated the InE of MSSA against ceftriaxone, cefepime, meropenem, ampicillin/sulbactam and piperacillin/tazobactam. The bacteraemic MSSA isolates were collected at ten Korean general hospitals from Sep 2013 to Mar 2015. The InE was defined if MICs of antibiotics at high inoculum (HI, ~5 × 10
7
CFU/ml) increased beyond the susceptible range compared to those at standard inoculum (SI, ~5 × 10
5
CFU/ml). All isolates were sequenced for
blaZ
gene typing. Among 302 MSSA isolates, 254 (84.1%) were positive for
blaZ
; types A, B, C and D were 13.6%, 26.8%, 43.4% and 0.3%, respectively. Mean HI MICs of all tested antibiotics were significantly increased and increases in HI MIC of piperacillin/tazobactam (HI, 48.14 ± 4.08 vs. SI, 2.04 ± 0.08 mg/L,
p
|
| doi_str_mv | 10.1007/s10096-018-3392-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2115273256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2113981749</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-1c0b204db0dfec6721261e89cfdb07bc9d51829ac2baa501a993f2a19fd8e1cd3</originalsourceid><addsrcrecordid>eNp1kc1u3CAURlHVqjNJ-gDdRJa66YaEC7YxyypKm5FGyiLNGmGME0bYOPws5u2DNWkrVcqGK8G5hwsfQl-BXAEh_DqWVbSYQIcZExS3H9AWatbgmnH2EW2JYDUWnLINOovxQEpPx_lntGGEtgI62CK_m73OLk-VGUejU-XHajLp2WrrnJ1xzFGbJdnemeohqeX56Lz2WudYqRzMWp6UnWOq-uDVgONSJKHoepMUdkonNVVqLgLrk9XxAn0alYvmy1s9R48_b3_f3OH9_a_dzY891jXrEgZNekrqoSdDmarlFGgLphN6LFu812JooKNCador1RBQQrCRKhDj0BnQAztH30_eJfiXbGKSky0vcU7NxucoKUBDOaNNW9Bv_6EHn8NcplspJjrgtSgUnCgdfIzBjHIJdlLhKIHINQ15SkOWNOSahlzNl2_m3E9m-Nvx5_sLQE9ALEfzkwn_rn7f-go5D5d7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2113981749</pqid></control><display><type>article</type><title>Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Song, Kyoung-Ho ; Jung, Sook-In ; Lee, Shinwon ; Park, Sohee ; Kim, Eu Suk ; Park, Kyung-Hwa ; Park, Wan Beom ; Choe, Pyoeng Gyun ; Kim, Young Keun ; Kwak, Yee Gyung ; Kim, Yeon-Sook ; Jang, Hee-Chang ; Kiem, Sungmin ; Kim, Hye-In ; Kim, Hong Bin</creator><creatorcontrib>Song, Kyoung-Ho ; Jung, Sook-In ; Lee, Shinwon ; Park, Sohee ; Kim, Eu Suk ; Park, Kyung-Hwa ; Park, Wan Beom ; Choe, Pyoeng Gyun ; Kim, Young Keun ; Kwak, Yee Gyung ; Kim, Yeon-Sook ; Jang, Hee-Chang ; Kiem, Sungmin ; Kim, Hye-In ; Kim, Hong Bin ; Korea INfectious Diseases (KIND) study group ; the Korea INfectious Diseases (KIND) study group</creatorcontrib><description>Scarce information concerning the inoculum effect (InE) of methicillin-susceptible
Staphylococcus aureus
(MSSA) against broad-spectrum β-lactam antibiotics is available. We investigated the InE of MSSA against ceftriaxone, cefepime, meropenem, ampicillin/sulbactam and piperacillin/tazobactam. The bacteraemic MSSA isolates were collected at ten Korean general hospitals from Sep 2013 to Mar 2015. The InE was defined if MICs of antibiotics at high inoculum (HI, ~5 × 10
7
CFU/ml) increased beyond the susceptible range compared to those at standard inoculum (SI, ~5 × 10
5
CFU/ml). All isolates were sequenced for
blaZ
gene typing. Among 302 MSSA isolates, 254 (84.1%) were positive for
blaZ
; types A, B, C and D were 13.6%, 26.8%, 43.4% and 0.3%, respectively. Mean HI MICs of all tested antibiotics were significantly increased and increases in HI MIC of piperacillin/tazobactam (HI, 48.14 ± 4.08 vs. SI, 2.04 ± 0.08 mg/L,
p
< 0.001) and ampicillin/sulbactam (HI, 24.15 ± 1.27 vs. SI, 2.79 ± 0.11 mg/L,
p
< 0.001) were most prominent. No MSSA isolates exhibited meropenem InE, and few isolates exhibited cefepime (0.3%) and ceftriaxone (2.3%) InE, whereas 43.0% and 65.9% of MSSA isolates exhibited piperacillin/tazobactam and ampicillin/sulbactam InE, respectively. About 93% of type C
blaZ
versus 45% of non-type C exhibited ampicillin/sulbactam InE (
p
< 0.001) and 88% of type C
blaZ
versus 9% of non-type C exhibited piperacillin/tazobactam InE (
p
< 0.001). A large proportion of MSSA clinical isolates, especially those positive for type C
blaZ
, showed marked ampicillin/sulbactam InE and piperacillin/tazobactam.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-018-3392-6</identifier><identifier>PMID: 30269181</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Amides ; Ampicillin ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Bacteremia - drug therapy ; Bacteremia - microbiology ; Bacteremia - mortality ; beta-Lactamases - genetics ; beta-Lactams - pharmacology ; beta-Lactams - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Cefepime ; Ceftriaxone ; Clinical isolates ; Humans ; Inoculum ; Internal Medicine ; Korea ; Medical Microbiology ; Meropenem ; Methicillin ; Microbial Sensitivity Tests ; Minimum inhibitory concentration ; Original Article ; Penicillin ; Piperacillin ; Staphylococcal Infections - drug therapy ; Staphylococcal Infections - microbiology ; Staphylococcal Infections - mortality ; Staphylococcus aureus ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - enzymology ; Staphylococcus aureus - genetics ; Sulbactam ; Tazobactam ; Typing ; β-Lactam antibiotics</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2019-01, Vol.38 (1), p.67-74</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2018</rights><rights>European Journal of Clinical Microbiology & Infectious Diseases is a copyright of Springer, (2018). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-1c0b204db0dfec6721261e89cfdb07bc9d51829ac2baa501a993f2a19fd8e1cd3</citedby><cites>FETCH-LOGICAL-c438t-1c0b204db0dfec6721261e89cfdb07bc9d51829ac2baa501a993f2a19fd8e1cd3</cites><orcidid>0000-0001-7652-7093</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-018-3392-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-018-3392-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30269181$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Song, Kyoung-Ho</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Lee, Shinwon</creatorcontrib><creatorcontrib>Park, Sohee</creatorcontrib><creatorcontrib>Kim, Eu Suk</creatorcontrib><creatorcontrib>Park, Kyung-Hwa</creatorcontrib><creatorcontrib>Park, Wan Beom</creatorcontrib><creatorcontrib>Choe, Pyoeng Gyun</creatorcontrib><creatorcontrib>Kim, Young Keun</creatorcontrib><creatorcontrib>Kwak, Yee Gyung</creatorcontrib><creatorcontrib>Kim, Yeon-Sook</creatorcontrib><creatorcontrib>Jang, Hee-Chang</creatorcontrib><creatorcontrib>Kiem, Sungmin</creatorcontrib><creatorcontrib>Kim, Hye-In</creatorcontrib><creatorcontrib>Kim, Hong Bin</creatorcontrib><creatorcontrib>Korea INfectious Diseases (KIND) study group</creatorcontrib><creatorcontrib>the Korea INfectious Diseases (KIND) study group</creatorcontrib><title>Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>Scarce information concerning the inoculum effect (InE) of methicillin-susceptible
Staphylococcus aureus
(MSSA) against broad-spectrum β-lactam antibiotics is available. We investigated the InE of MSSA against ceftriaxone, cefepime, meropenem, ampicillin/sulbactam and piperacillin/tazobactam. The bacteraemic MSSA isolates were collected at ten Korean general hospitals from Sep 2013 to Mar 2015. The InE was defined if MICs of antibiotics at high inoculum (HI, ~5 × 10
7
CFU/ml) increased beyond the susceptible range compared to those at standard inoculum (SI, ~5 × 10
5
CFU/ml). All isolates were sequenced for
blaZ
gene typing. Among 302 MSSA isolates, 254 (84.1%) were positive for
blaZ
; types A, B, C and D were 13.6%, 26.8%, 43.4% and 0.3%, respectively. Mean HI MICs of all tested antibiotics were significantly increased and increases in HI MIC of piperacillin/tazobactam (HI, 48.14 ± 4.08 vs. SI, 2.04 ± 0.08 mg/L,
p
< 0.001) and ampicillin/sulbactam (HI, 24.15 ± 1.27 vs. SI, 2.79 ± 0.11 mg/L,
p
< 0.001) were most prominent. No MSSA isolates exhibited meropenem InE, and few isolates exhibited cefepime (0.3%) and ceftriaxone (2.3%) InE, whereas 43.0% and 65.9% of MSSA isolates exhibited piperacillin/tazobactam and ampicillin/sulbactam InE, respectively. About 93% of type C
blaZ
versus 45% of non-type C exhibited ampicillin/sulbactam InE (
p
< 0.001) and 88% of type C
blaZ
versus 9% of non-type C exhibited piperacillin/tazobactam InE (
p
< 0.001). A large proportion of MSSA clinical isolates, especially those positive for type C
blaZ
, showed marked ampicillin/sulbactam InE and piperacillin/tazobactam.</description><subject>Amides</subject><subject>Ampicillin</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - mortality</subject><subject>beta-Lactamases - genetics</subject><subject>beta-Lactams - pharmacology</subject><subject>beta-Lactams - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cefepime</subject><subject>Ceftriaxone</subject><subject>Clinical isolates</subject><subject>Humans</subject><subject>Inoculum</subject><subject>Internal Medicine</subject><subject>Korea</subject><subject>Medical Microbiology</subject><subject>Meropenem</subject><subject>Methicillin</subject><subject>Microbial Sensitivity Tests</subject><subject>Minimum inhibitory concentration</subject><subject>Original Article</subject><subject>Penicillin</subject><subject>Piperacillin</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Staphylococcal Infections - microbiology</subject><subject>Staphylococcal Infections - mortality</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - enzymology</subject><subject>Staphylococcus aureus - genetics</subject><subject>Sulbactam</subject><subject>Tazobactam</subject><subject>Typing</subject><subject>β-Lactam antibiotics</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1u3CAURlHVqjNJ-gDdRJa66YaEC7YxyypKm5FGyiLNGmGME0bYOPws5u2DNWkrVcqGK8G5hwsfQl-BXAEh_DqWVbSYQIcZExS3H9AWatbgmnH2EW2JYDUWnLINOovxQEpPx_lntGGEtgI62CK_m73OLk-VGUejU-XHajLp2WrrnJ1xzFGbJdnemeohqeX56Lz2WudYqRzMWp6UnWOq-uDVgONSJKHoepMUdkonNVVqLgLrk9XxAn0alYvmy1s9R48_b3_f3OH9_a_dzY891jXrEgZNekrqoSdDmarlFGgLphN6LFu812JooKNCador1RBQQrCRKhDj0BnQAztH30_eJfiXbGKSky0vcU7NxucoKUBDOaNNW9Bv_6EHn8NcplspJjrgtSgUnCgdfIzBjHIJdlLhKIHINQ15SkOWNOSahlzNl2_m3E9m-Nvx5_sLQE9ALEfzkwn_rn7f-go5D5d7</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Song, Kyoung-Ho</creator><creator>Jung, Sook-In</creator><creator>Lee, Shinwon</creator><creator>Park, Sohee</creator><creator>Kim, Eu Suk</creator><creator>Park, Kyung-Hwa</creator><creator>Park, Wan Beom</creator><creator>Choe, Pyoeng Gyun</creator><creator>Kim, Young Keun</creator><creator>Kwak, Yee Gyung</creator><creator>Kim, Yeon-Sook</creator><creator>Jang, Hee-Chang</creator><creator>Kiem, Sungmin</creator><creator>Kim, Hye-In</creator><creator>Kim, Hong Bin</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7652-7093</orcidid></search><sort><creationdate>20190101</creationdate><title>Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics</title><author>Song, Kyoung-Ho ; Jung, Sook-In ; Lee, Shinwon ; Park, Sohee ; Kim, Eu Suk ; Park, Kyung-Hwa ; Park, Wan Beom ; Choe, Pyoeng Gyun ; Kim, Young Keun ; Kwak, Yee Gyung ; Kim, Yeon-Sook ; Jang, Hee-Chang ; Kiem, Sungmin ; Kim, Hye-In ; Kim, Hong Bin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-1c0b204db0dfec6721261e89cfdb07bc9d51829ac2baa501a993f2a19fd8e1cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Amides</topic><topic>Ampicillin</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - mortality</topic><topic>beta-Lactamases - genetics</topic><topic>beta-Lactams - pharmacology</topic><topic>beta-Lactams - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cefepime</topic><topic>Ceftriaxone</topic><topic>Clinical isolates</topic><topic>Humans</topic><topic>Inoculum</topic><topic>Internal Medicine</topic><topic>Korea</topic><topic>Medical Microbiology</topic><topic>Meropenem</topic><topic>Methicillin</topic><topic>Microbial Sensitivity Tests</topic><topic>Minimum inhibitory concentration</topic><topic>Original Article</topic><topic>Penicillin</topic><topic>Piperacillin</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Staphylococcal Infections - microbiology</topic><topic>Staphylococcal Infections - mortality</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - enzymology</topic><topic>Staphylococcus aureus - genetics</topic><topic>Sulbactam</topic><topic>Tazobactam</topic><topic>Typing</topic><topic>β-Lactam antibiotics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Song, Kyoung-Ho</creatorcontrib><creatorcontrib>Jung, Sook-In</creatorcontrib><creatorcontrib>Lee, Shinwon</creatorcontrib><creatorcontrib>Park, Sohee</creatorcontrib><creatorcontrib>Kim, Eu Suk</creatorcontrib><creatorcontrib>Park, Kyung-Hwa</creatorcontrib><creatorcontrib>Park, Wan Beom</creatorcontrib><creatorcontrib>Choe, Pyoeng Gyun</creatorcontrib><creatorcontrib>Kim, Young Keun</creatorcontrib><creatorcontrib>Kwak, Yee Gyung</creatorcontrib><creatorcontrib>Kim, Yeon-Sook</creatorcontrib><creatorcontrib>Jang, Hee-Chang</creatorcontrib><creatorcontrib>Kiem, Sungmin</creatorcontrib><creatorcontrib>Kim, Hye-In</creatorcontrib><creatorcontrib>Kim, Hong Bin</creatorcontrib><creatorcontrib>Korea INfectious Diseases (KIND) study group</creatorcontrib><creatorcontrib>the Korea INfectious Diseases (KIND) study group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Song, Kyoung-Ho</au><au>Jung, Sook-In</au><au>Lee, Shinwon</au><au>Park, Sohee</au><au>Kim, Eu Suk</au><au>Park, Kyung-Hwa</au><au>Park, Wan Beom</au><au>Choe, Pyoeng Gyun</au><au>Kim, Young Keun</au><au>Kwak, Yee Gyung</au><au>Kim, Yeon-Sook</au><au>Jang, Hee-Chang</au><au>Kiem, Sungmin</au><au>Kim, Hye-In</au><au>Kim, Hong Bin</au><aucorp>Korea INfectious Diseases (KIND) study group</aucorp><aucorp>the Korea INfectious Diseases (KIND) study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>38</volume><issue>1</issue><spage>67</spage><epage>74</epage><pages>67-74</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>Scarce information concerning the inoculum effect (InE) of methicillin-susceptible
Staphylococcus aureus
(MSSA) against broad-spectrum β-lactam antibiotics is available. We investigated the InE of MSSA against ceftriaxone, cefepime, meropenem, ampicillin/sulbactam and piperacillin/tazobactam. The bacteraemic MSSA isolates were collected at ten Korean general hospitals from Sep 2013 to Mar 2015. The InE was defined if MICs of antibiotics at high inoculum (HI, ~5 × 10
7
CFU/ml) increased beyond the susceptible range compared to those at standard inoculum (SI, ~5 × 10
5
CFU/ml). All isolates were sequenced for
blaZ
gene typing. Among 302 MSSA isolates, 254 (84.1%) were positive for
blaZ
; types A, B, C and D were 13.6%, 26.8%, 43.4% and 0.3%, respectively. Mean HI MICs of all tested antibiotics were significantly increased and increases in HI MIC of piperacillin/tazobactam (HI, 48.14 ± 4.08 vs. SI, 2.04 ± 0.08 mg/L,
p
< 0.001) and ampicillin/sulbactam (HI, 24.15 ± 1.27 vs. SI, 2.79 ± 0.11 mg/L,
p
< 0.001) were most prominent. No MSSA isolates exhibited meropenem InE, and few isolates exhibited cefepime (0.3%) and ceftriaxone (2.3%) InE, whereas 43.0% and 65.9% of MSSA isolates exhibited piperacillin/tazobactam and ampicillin/sulbactam InE, respectively. About 93% of type C
blaZ
versus 45% of non-type C exhibited ampicillin/sulbactam InE (
p
< 0.001) and 88% of type C
blaZ
versus 9% of non-type C exhibited piperacillin/tazobactam InE (
p
< 0.001). A large proportion of MSSA clinical isolates, especially those positive for type C
blaZ
, showed marked ampicillin/sulbactam InE and piperacillin/tazobactam.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30269181</pmid><doi>10.1007/s10096-018-3392-6</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-7652-7093</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2019-01, Vol.38 (1), p.67-74 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2115273256 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Amides Ampicillin Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Bacteremia - drug therapy Bacteremia - microbiology Bacteremia - mortality beta-Lactamases - genetics beta-Lactams - pharmacology beta-Lactams - therapeutic use Biomedical and Life Sciences Biomedicine Cefepime Ceftriaxone Clinical isolates Humans Inoculum Internal Medicine Korea Medical Microbiology Meropenem Methicillin Microbial Sensitivity Tests Minimum inhibitory concentration Original Article Penicillin Piperacillin Staphylococcal Infections - drug therapy Staphylococcal Infections - microbiology Staphylococcal Infections - mortality Staphylococcus aureus Staphylococcus aureus - drug effects Staphylococcus aureus - enzymology Staphylococcus aureus - genetics Sulbactam Tazobactam Typing β-Lactam antibiotics |
| title | Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T21%3A10%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inoculum%20effect%20of%20methicillin-susceptible%20Staphylococcus%20aureus%20against%20broad-spectrum%20beta-lactam%20antibiotics&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Song,%20Kyoung-Ho&rft.aucorp=Korea%20INfectious%20Diseases%20(KIND)%20study%20group&rft.date=2019-01-01&rft.volume=38&rft.issue=1&rft.spage=67&rft.epage=74&rft.pages=67-74&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-018-3392-6&rft_dat=%3Cproquest_cross%3E2113981749%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2113981749&rft_id=info:pmid/30269181&rfr_iscdi=true |